Mitophagy Probes Development Service
Mitophagy is a selective mitochondrial quality-control process that removes damaged or dysfunctional mitochondria through autophagy-lysosome pathways. MitoGlowing™ provides a comprehensive Mitophagy Probes Development Service to support custom mitophagy probe design, reporter system development, enzyme-activatable probe optimization, biological validation, live-cell and fixed-cell imaging workflows, and high-content screening assays for mitochondrial quality-control research, drug discovery, neurodegenerative disease studies, cardiometabolic disease models, and cancer therapy evaluation.
Introduction to Mitophagy Probes
Mitophagy plays an essential role in maintaining mitochondrial homeostasis by eliminating damaged mitochondria and preventing excessive oxidative stress, metabolic dysfunction, and cell death. Dysregulated mitophagy is associated with neurodegeneration, cardiovascular injury, ocular neurodegeneration, cancer progression, aging-related disorders, inflammatory disease, and drug-induced mitochondrial damage.
Mitophagy probes are designed to convert mitochondrial delivery into lysosomes, mitochondrial degradation, mitophagic flux, or mitochondrial quality-control activity into measurable fluorescence or imaging readouts. Classical approaches include pH-sensitive mitophagy dyes, tandem fluorescent protein reporters, ΔΨm-dependent mitochondrial probes, lysosome-sensitive probes, mito-QC-like systems, mito-Keima-related systems, and mito-SRAI-like reporters.
Recent probe strategies aim to improve signal persistence, specificity, quantification, and compatibility with fixed samples and high-throughput imaging. pH-independent, enzyme-activatable, tandem fluorescent, or signal-stabilized probe systems can reduce uncertainty caused by lysosomal pH fluctuation, mitochondrial depolarization, incomplete flux, or signal loss under stress conditions.
Fig.1 G-Mito and R-Lyso's chemical compositions and proposed response mechanism to detect mitophagy.
Features of Mitophagy Probes Development
- Mitophagy-specific readout design for mitophagosome formation, mitochondria-to-lysosome delivery, mitolysosome generation, mitophagic flux, and mitochondrial degradation.
- pH-independent and signal-sustained probe strategies based on enzyme-activatable, covalently retained, tandem reporter, or signal-stabilized systems.
- Live-cell and fixed-cell imaging compatibility for real-time imaging, long-term monitoring, endpoint assays, high-content imaging, and automated image analysis.
- Mitochondrial quality-control assay development for PINK1/Parkin-dependent mitophagy, receptor-mediated mitophagy, lysosomal flux, autophagosome accumulation, mitochondrial fragmentation, and mitochondrial damage response.
- High-content drug screening compatibility in 96-well and 384-well imaging assays for mitophagy inducer screening, inhibitor evaluation, mitochondrial toxicity testing, and therapeutic mechanism studies.
- Application-specific biological validation in neurodegeneration, diabetic cardiomyopathy, ocular disease, cancer therapy, hypoxia models, cardiomyocyte injury, mitochondrial dysfunction, and oxidative stress models.
Our Services
MitoGlowing™ provides an integrated mitophagy probe development workflow covering project strategy, probe or reporter design, photophysical and functional characterization, biological validation, imaging assay development, and application-specific optimization.
Project Design & Mitophagy Readout Strategy
- Define the target application, such as mitochondrial quality-control imaging, drug screening, neurodegeneration research, cardiomyopathy models, ocular disease studies, or cancer therapy evaluation.
- Select the preferred mitophagy readout, including pH-sensitive, pH-independent, enzyme-activatable, tandem fluorescent, genetically encoded, lipid-labeling, or fixed-cell-compatible probe systems.
- Determine key performance requirements, including signal persistence, specificity, mitochondrial localization, lysosomal activation, photostability, response kinetics, cytotoxicity, and imaging platform compatibility.
- Design validation strategies using CCCP, oligomycin/antimycin A, rotenone, hypoxia, oxidative stress, mitochondrial damage inducers, lysosomal inhibitors, autophagy modulators, and pathway controls.
Probe, Reporter & Labeling System Development
- Design mitophagy-responsive probes based on mitochondrial targeting motifs, pH-sensitive dyes, enzyme-activatable fluorophores, tandem fluorescent proteins, lipid-labeling chemistry, or lysosome-activated signal platforms.
- Develop reporter workflows inspired by mito-Keima, mito-QC, mito-SRAI, Mtphagy Dye, ECAM-like systems, or customized synthetic fluorescent probes.
- Introduce mitochondrial localization groups, retention mechanisms, lysosome-activated response modules, covalent immobilization handles, red/NIR fluorophores, or ratiometric signal units.
- Optimize cell permeability, mitochondrial accumulation, retention stability, lysosomal signal activation, background suppression, and biological compatibility.
Photophysical & Functional Characterization
- Measure absorption spectra, emission spectra, excitation/emission maxima, Stokes shift, fluorescence intensity, quantum yield, signal stability, and spectral separation.
- Evaluate pH response, enzyme activation, lysosomal stability, mitochondrial retention, photostability, response kinetics, signal persistence, and background fluorescence.
- Test probe behavior under mitochondrial depolarization, lysosomal acidification, autophagy inhibition, oxidative stress, nutrient stress, hypoxia, and mitochondrial fragmentation conditions.
- Assess compatibility with co-staining probes such as membrane potential probes, lysosome markers, ROS probes, ATP/ADP probes, calcium probes, and nuclear dyes.
Biological Validation & Mitophagy Assay Development
- Validate mitochondrial localization, lysosomal delivery, mitolysosome signal generation, mitophagic flux response, and co-localization with mitochondrial and lysosomal markers.
- Optimize staining concentration, probe loading time, reporter expression conditions, washing steps, stimulation timing, fixation conditions, imaging settings, and acquisition parameters.
- Test probe response in PINK1/Parkin activation models, receptor-mediated mitophagy models, hypoxia-induced mitophagy, oxidative stress models, and drug-induced mitochondrial damage systems.
- Establish quantitative analysis methods, including mitophagy index, mitolysosome area, red/green ratio, puncta count, co-localization, time-course tracking, dose-response curves, and image-based scoring.
Supported Sample Types and Models
- Ocular disease models, including retinal cells, retinal ganglion cell models, glaucoma-related models, and retinal degeneration systems
- Cancer cell lines, tumor spheroids, organoids, and hypoxic tumor models
- Mitochondrial dysfunction, oxidative stress, depolarization, and lysosomal flux models
- Diabetic cardiomyopathy and high-glucose-induced mitochondrial injury models
- Neuronal and neurodegenerative disease models, including SH-SY5Y cells, PC12 cells, primary neurons, and brain slices
- Cardiomyocyte models, including H9C2 cells, primary cardiomyocytes, and iPSC-derived cardiomyocytes
- Immune cells, hepatocytes, renal tubular cells, stem cells, and 3D culture systems
- Drug-treated, hypoxia-treated, nutrient-stressed, oxidative stress-treated, or nanomaterial-treated cells
- Zebrafish embryos, tissue sections, and selected small animal research models
- 96-well, 384-well, live-cell imaging, fixed-cell imaging, and high-content screening formats
Application
Signal-Sustained Mitophagy Imaging and Drug Screening
Signal persistence is a key challenge in mitophagy imaging because many conventional probes depend on lysosomal pH changes or mitochondrial membrane potential loss. Enzyme-activatable and signal-retained probe strategies can support pH-independent mitophagy readouts, fixed-cell compatibility, and high-content screening of mitophagy inducers or inhibitors.
This application supports mitophagy probe development for drug screening, mitophagy inducer discovery, fixed-cell assay development, mitochondrial quality-control research, and pH-independent mitophagy readout design.
Dual-Responsive Probes for Diabetic Cardiomyopathy Drug Screening
Diabetic cardiomyopathy is closely associated with mitochondrial dysfunction, oxidative stress, and altered mitophagy. Dual-responsive fluorescent probe strategies can combine ROS and mitophagy readouts to support multi-target drug screening in high-glucose cardiomyocyte models.
This application supports probe development for diabetic cardiomyopathy research, ROS-mitophagy dual readouts, natural compound screening, Drp1-related mitochondrial quality-control studies, cardiomyocyte mitochondrial protection assays, and high-throughput drug evaluation.
Mitophagy Reporter Systems for Ocular Neurodegeneration Research
Mitophagy dysregulation is increasingly studied in ocular neurodegenerative diseases such as glaucoma, age-related macular degeneration, diabetic retinopathy, and retinal degeneration. Reporter systems such as mito-SRAI-like platforms can help bridge cell-based assays and animal model research.
This application supports mitophagy reporter development for retinal disease models, glaucoma-related neurodegeneration, ocular drug screening, mitochondrial quality-control biomarker research, and translation from cell-based assays to animal models.
Mitophagy Regulation in Hypoxic Tumor Therapy
Mitophagy regulation can be used as a therapeutic strategy in hypoxic tumors. Hypoxia-responsive nanomedicine, photodynamic therapy, mitophagy blockade, and mitochondria-targeted treatments can be evaluated using mitophagy probes together with ROS, membrane potential, apoptosis, and viability readouts.
This application supports mitophagy probe development for cancer therapy evaluation, hypoxia-responsive nanomedicine, photodynamic therapy monitoring, mitophagy blockade studies, tumor oxidative stress profiling, and theranostic probe development.
Our Advantages
- Integrated mitophagy probe and reporter development: We combine synthetic probe design, reporter workflow development, enzyme-activatable chemistry, photophysical characterization, biological validation, and image-based assay optimization.
- Mitochondrial dynamics and quality-control expertise: Our platform supports mitophagy probe development for PINK1/Parkin signaling, mitochondrial damage response, lysosomal flux, mitochondrial degradation, mitophagy induction, and mitophagy blockade.
- Flexible mitophagy readout design: We support pH-sensitive, pH-independent, enzyme-activatable, tandem fluorescent, genetically encoded, red/NIR, live-cell, fixed-cell, and high-content imaging-compatible mitophagy probe strategies.
- Application-oriented assay optimization: Probe performance can be tailored for drug screening, neurodegeneration, cardiometabolic disease, ocular disease, cancer therapy, nanomedicine, organoids, tissue imaging, and high-content screening.
- Multi-parameter mitochondrial QC profiling: Mitophagy probe assays can be integrated with mitochondrial membrane potential, ROS, ATP/ADP, NADH/NAD⁺, calcium, pH, lysosomal function, apoptosis, cell viability, and mitochondrial morphology assays.
Contact Us
Develop sensitive, reliable, and application-specific mitophagy probes with Protheragen's Mitophagy Probes Development Service. Contact us with your target model, preferred mitophagy readout, imaging platform, live-cell or fixed-cell requirement, pathway of interest, throughput requirement, and research objective. Our team will recommend a tailored probe or assay development strategy for mitochondrial quality-control imaging, mitophagy drug screening, neurodegeneration research, cardiometabolic disease models, cancer therapy evaluation, and high-content mitochondrial profiling.
Reference
1. Liu, Y., et al. (2023). Advances in Small-Molecule Fluorescent pH Probes for Monitoring Mitophagy. Chemical & biomedical imaging, 2(2), 81–97.
